Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
Tuesday 14 April 2026 4:13 pm

Acumetis Launches as a Single Integrated Brand to Transform Life Sciences Commercialization

Acumetis – a new global commercialization company for the life sciences industry – launches today. The company, formed as a combination of five well-known specialist consultancies – Herspiegel, Adivo Associates, Decisive Consulting, Fiecon, and Sixsense Strategy Group – will provide enhanced strategic clarity and critical connection for life sciences businesses with products at all stages of development.

Acumetis is built around a single integrated commercial model and one leadership team, bringing together commercial, insights, medical, market access and patient strategy under one roof. The business offers capability and data to support clients across the product lifecycle, from evaluation and market access strategy through to launch execution and in-market performance.

Acumetis is purposefully built for the demands of modern life sciences commercialization. The name reflects the company’s founding philosophy. ‘Acumen’ – the ability to make good judgments and discern what really matters – and ‘Metis’, the Greek concept of practical wisdom, together define an approach built on rigorous analysis, connected expertise, and measurable results for clients.

Brent Herspiegel, CEO of Acumetis, said: “Acumetis is designed to set a new standard in commercialization. Not just in capability, but in how that capability is delivered. For over two decades, the businesses that form Acumetis have supported more than 200 product launches for some of the most complex and high-stakes assets in life sciences. We’re now bringing our clients our full expertise as one integrated brand, helping them to make the right decision at the moments that matter most. For life sciences companies facing compressed timelines, increasing regulatory complexity and rising pressure to demonstrate value, this is a compelling value proposition.”

As a combined business, Acumetis will employ more than 350 specialists globally, with operational experience spanning more than 50 geographic markets. The company’s client base already includes more than 150 life sciences organizations, among them many of the world’s top global pharmaceutical companies. The founding businesses have collectively supported more than 200 product launches and years of commercialization success.

The company is backed by DFW Capital, a leading middle-market private equity firm investing in companies that provide outsourced business, industrial, or healthcare services in regulated, compliance driven end-markets.

Acumetis is headquartered in Yardley, Pennsylvania, with additional offices across the United States, Canada, South America, United Kingdom, Europe and India. The company’s website launches today at www.acumetisglobal.com.

Further information is available at www.acumetisglobal.com. Media enquiries should be directed to [email protected].

About Acumetis

Acumetis is a global expert commercialization partner purposefully built to help life sciences win in the age of connectivity. With an integrated model spanning the entire asset lifecycle, deep functional and therapeutic-area expertise, and rigorous, outcome-driven thinking, Acumetis reframes complex problems and shapes solutions that are both imaginative and achievable. With more than 350 experts globally and experience across 50+ geographic markets, Acumetis helps clients unlock value, accelerate performance, and deliver better outcomes for patients.

Acumetis. Reframe what’s possible.

About DFW Capital

DFW Capital Partners is a middle-market private equity firm with over $2 billion in assets under management. The firm’s focus for the past 20 years has been investing in founder or management owned companies that provide outsourced business, industrial, or healthcare services in regulated, compliance driven end-markets.

Acumetis brand launch event showcasing pharmaceutical and biotech leaders uniting for life sciences commercialization

View source version on businesswire.com: https://www.businesswire.com/news/home/20260414569348/en/

Contact

[email protected]
+44 7861995400

Abstract

LEADING PHARMACEUTICAL AND BIOTECH CONSULTANCIES COMBINE TO CREATE A FULL-SERVICE COMMERCIALIZATION POWERHOUSE, ACUMETIS

TweetText

Acumetis is formed as a combination of five well-known specialist consultancies – Herspiegel, Adivo Associates, Decisive Consulting, Fiecon, and Sixsense Strategy Group.

Company Logo
Company Logo
Read more

Real Chemistry Unifies Omnichannel Offering as Real Chemistry Media, a Technology-led, Healthcare-focused Practice of the Future

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Businesswire

Categories

  • Merger/Acquisition

Trending Articles

  • Revealed: Secret Treasury plan to tax State Pension before it is paid out

  • Two solicitors linked to Post Office scandal charged with misconduct

  • Burnham’s new chief of staff ran City firm advising Thames Water and rival Heathrow bidder

  • Barclays and Lloyds join banking sector plan for digital ID

  • Reeves’ new tax charge on cash ISAs faces fierce industry backlash

More from City PM

  • Real Chemistry Unifies Omnichannel Offering as Real Chemistry Media, a Technology-led, Healthcare-focused Practice of the Future

    Business Wire
  • Paladin Deepens Allied Supply Chain Footprint with South Korea Strategic Initiative and Netherlands Expansion, Advances Ex-China Rare Earth Recovery

    Business Wire
  • H55 Delivers Certification-Grade Propulsion Battery Modules to Pratt & Whitney Canada, Supporting Demonstration of Hybrid-Electric Aircraft Technology

    Business Wire
  • Type One Energy Appoints Bernard Looney to Board of Directors

    Business Wire
  • Frost & Sullivan 2026 Technology Innovation Leadership Best Practices Recognition for Ohmium International

    Business Wire
  • Fasanara Capital Launches Investment Platform for Ferrari-backed Lending

    Business Wire
  • Starmer agrees investment deal with Japan as EU deal questioned

    Politics
    UK and Japan leaders discuss bilateral trade agreements at a high-level government meeting in London.
  • SpaceX: To boldly go where no investor comms strategy has gone before

    Opinion
    Elon Musk discussing SpaceX investment as Scottish Mortgages largest holding on a business news platform

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM. All rights reserved.
About · Contact · Terms · Privacy